Cipla Launches AI-Powered Mobile App for Asthma Screening

Available on Android and soon to be launched for iOS, CipAir is integrated with the company’s Breathefree platform, a comprehensive respiratory care ecosystem.

Cipla has introduced CipAir, an AI-powered mobile application designed to provide an accessible and clinically validated screening tool for asthma. 

Available on Android and soon to be launched for iOS, CipAir is integrated with the company’s Breathefree platform, a comprehensive respiratory care ecosystem.

The CipAir application employs a proprietary algorithm that combines acoustic signature analysis and artificial neural network technology. Users can conduct a screening by performing three guided exhalations into their mobile handset in a quiet environment. 

The application processes these inputs to determine the likelihood of asthma, offering results that indicate the presence, absence, or potential future onset of the condition.

Speaking on the innovation, Umang Vohra, Managing Director & Global CEO of Cipla, said, “At Cipla, our approach to healthcare is deeply rooted in innovation. By leveraging the power of next-gen technologies, we are developing solutions that are fundamentally transforming patient care and enabling better diagnostic, treatment, and management outcomes. Patient-centricity is at the heart of what we do, and CipAir’s AI-led technology is yet another step forward in making personalized healthcare accessible and user-friendly, thereby empowering them to live fuller lives.”

Empowering Patients for Timely Interventions

The application not only provides screening results but also equips users with valuable information about lung health and connects them with experts through the Breathefree platform. 

This aims to facilitate timely interventions and better management of respiratory health.

Achin Gupta, CEO, One India Business, Cipla, remarked, “CipAir is a powerful clinically validated tool that puts health in the hands of patients and enables timely intervention against asthma so that they don’t have to compromise on their quality of life. As lung leaders, it is our firm resolve to help India tackle its growing asthma burden and breathe free through such cutting-edge solutions that strengthen the asthma care ecosystem.”

Strengthening India’s Asthma Care Ecosystem

Asthma remains a significant public health challenge in India. Cipla's launch of CipAir underscores the company’s commitment to enhancing the asthma care ecosystem through innovative solutions that prioritize accessibility and patient-centricity. 

The integration of CipAir within the Breathefree platform further strengthens its utility as a comprehensive tool for respiratory care

With the promise of timely diagnosis and actionable insights, CipAir offers a step forward in addressing India’s growing asthma burden, reinforcing Cipla’s position in the respiratory healthcare space.